 "Pharma")
About a year since the National Pharma Pricing Authority (NPPA) put a price cap on coronary stents, medical devices industry is making a slow move to self-regulation by capping trade margins. Syringes and needles makers have put a cap of 75 per cent on trade margins, effective Republic Day, to avoid the wrath of pharma pricing regulator. The NPPA put a price cap on coronary stents and orthopaedic implants last year.
Also, it forced over 15 other device makers to finally put a maximum retail price on devices for the first time to avoid overcharging by hospitals.
Vimal Khemka, who
